目的 分析新型冠状病毒肺炎（COVID-19）患者死亡的影响因素，为临床上减少COVID-19患者的病亡率提供参考。方法 回顾性分析本院2020年1月17日-2月25日期间所有COVID-19入院患者的病例资料，收集患者的性别、年龄、住院期间是否服用中药制剂、临床分型、合并症、核酸检测结果、入院时间、出院情况等相关指标进行统计分析。结果 COVID-19疫情期间，本院COVID-19患者的在院人数逐渐增多，最高峰期曾同时收治904名COVID-19患者。在2020年1月17日-2月25日期间本院共收治1 305例COVID-19患者，其中男性632例，女性673例，男女比例1：1.06。年龄分布在7~101岁，中位数为63（51，70）岁。不同性别之间，患者的年龄分布无明显差异。单因素分析结果显示患者的性别、年龄、治疗期间是否服用中药制剂、临床分型、是否合并基础疾病（高血压、冠心病、糖尿病、肿瘤及尿毒症）以及核酸检测结果均可影响患者的病亡率。Logistics多因素回归分析发现，服用中药制剂、临床分型以及是否合并基础疾病是COVID-19患者病亡的独立危险因素。结论 COVID-19患者死亡与多种因素有关，减少危重症的发生，控制基础疾病，稳定血压血糖，积极改善心脑血管条件及稳定肾功能等是提高COVID-19患者治疗效果的主要措施，并且早期应用中药治疗对减少COVID-19病亡率同样具有十分重要的作用。

Objective To analyze the influencing factors of death in patients with coronavirus disease 2019 (COVID-19) and provide a reference for clinically reducing the mortality of patients with COVID-19. Methods Based on the retrospective analysis of the case data of all patients with COVID-19 admitted in our hospital from January 17th to February 25th, 2020, and the sex, age, whether or not to take Chinese medicine preparations during hospitalization, clinical classification, comorbidities, nucleic acid test results, admission time, discharge and other relevant indicators were collected for statistical analysis. Results During the period of COVID-19, the number of patients of COVID-19 in our hospital gradually increased. At the epidemic peak period, 904 patients with COVID-19 were treated simultaneously. From January 17th to February 25th, 2020, a total of 1 305 patients with COVID-19 were treated in our hospital, including 632 males and 673 females, and the male to female ratio was 1:1.06. The age distribution ranged from 7 to 111 years, with a median of 63 (51, 70) years old. There was no significant difference in the age distribution of patients between different genders (Z=1.217, P=0.224). The results of univariate analysis showed that the patient's gender, age, whether to take Chinese medicine preparations during treatment, clinical classification, whether combined with underlying diseases (hypertension, coronary heart disease, diabetes, tumors and uremia) and nucleic acid test results all could affect patients fatality rate. Logistics multivariate regression analysis found that taking traditional Chinese medicine preparations, clinical classification, and whether combined with underlying diseases were independent risk factors for death in patients with COVID-19. Conclusion The death of patients with COVID-19 is related to various factors. Reducing the occurrence of critical illness, controlling underlying diseases, stabilizing blood pressure and blood sugar, actively improving cardio-cerebral vascular conditions, and stabilizing renal function are main measures to improve the therapeutic effect, and early application of traditional Chinese medicine treatment also plays a very important role in reducing the mortality of patients with COVID-19.

R254.2